← Back to patent-cliff list
AUS-131
Tier C — Watch / tradeAUS-131
Ausio Pharmaceuticals Llc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ERβ
Indications (approved)：Cerebrovascular disease, Mild cognitive impairment, 动脉硬化, 脑白质病, Cognitive impairment, Chronic renal impairment, Alzheimer's disease, Breast cancer
Regional status
US
Phase II
2009-06-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of AUS-131?
Approved indications include: Cerebrovascular disease, Mild cognitive impairment, 动脉硬化, 脑白质病, Cognitive impairment, Chronic renal impairment, Alzheimer's disease, Breast cancer.
When does the AUS-131 patent expire?
No public expiry year is available for AUS-131 yet; this page updates once verified.
How do I get a quote for AUS-131 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21